Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery (OSPREY)

This study is ongoing, but not recruiting participants.
ClinLogix. LLC
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Information provided by (Responsible Party):
Terumo Medical Corporation Identifier:
First received: May 4, 2010
Last updated: July 13, 2015
Last verified: July 2015
Results First Received: June 18, 2015  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Peripheral Vascular Disease
Intervention: Device: Misago™ Self-Expanding Stent System

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 276 subjects were enrolled including 261 subjects in the pivotal cohort and 15 subjects implanted with a single, 150mm stent as part of a long length stent sub-study. Subject data for the long length stent sub-study is not yet available.

Reporting Groups
Misago™ Self-Expanding Stent System Subjects received treatment with the Misago™ Self-Expanding Stent

Participant Flow:   Overall Study
    Misago™ Self-Expanding Stent System
STARTED   261 
Death                8 
Lost to Follow-up                6 
Missed 12 Month Visit                7 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Non-Randomized Misago™ Self-Expanding Stent System: Transcatheter placement of an intravascular stent(s)

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Standard Deviation)
 69.3  (10) 
[Units: Participants]
Female   92 
Male   169 
Region of Enrollment 
[Units: Participants]
United States   201 
Japan   50 
Taiwan   9 
Korea, Republic of   1 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Primary Effectiveness Endpoint   [ Time Frame: 12 Months post-procedure ]

2.  Primary:   Primary Safety Endpoint   [ Time Frame: 30 days post-procedure ]

3.  Secondary:   Primary Effectiveness Endpoint in Modified Intent-to-Treat (mITT) Cohort   [ Time Frame: 12 Months post-procedure ]

4.  Secondary:   Primary Effectiveness Endpoint Using a Peak Systolic Velocity Ratio of ≤ 2.4 (i.e., Modified VIVA Criteria) in the mITT Cohort   [ Time Frame: 12 Months post-procedure ]

5.  Secondary:   Occurrence of Target Lesion Revascularization   [ Time Frame: 12 Months post-procedure ]

6.  Secondary:   Device Related Peri-Procedural Complications   [ Time Frame: Prior to Hosptial Discharge ]

7.  Secondary:   Technical Success   [ Time Frame: Intra-procedure ]

8.  Secondary:   Procedural Success   [ Time Frame: Intra-procedure ]

9.  Secondary:   Clinical Success   [ Time Frame: 30 days post-procedure ]

10.  Secondary:   Major Adverse Events (MAEs) Through 12 Months Post-procedure   [ Time Frame: 12 Months post-procedure ]

11.  Secondary:   Stent Fracture at 12 Months   [ Time Frame: 12 Months post-procedure ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Adam Thompson, Clinical Project Manager
Organization: Terumo Medical Corporation
phone: 201-398-3283

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Terumo Medical Corporation Identifier: NCT01118117     History of Changes
Other Study ID Numbers: TIS2009-02
Study First Received: May 4, 2010
Results First Received: June 18, 2015
Last Updated: July 13, 2015
Health Authority: United States: Food and Drug Administration